Cuban Monoclonal Antibody Registered in China

TheraCIM h-R3, a humanized monoclonal antibody, received the certificate of first-category drug granted by the State Food and Drug Administration of China, for its production and commercialization in that Asian nation. According to Prensa Latina news agency, the drug is prescribed for the combined treatment of advanced head and neck epithelial cancer, of bad prognosis and resistant to the chemotherapy, explained PhD. Patricia Sierra, responsible on the Cuban side of this project.

Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=2a5d7d8738f0061b&cat=6dcd932030878143)